$5.67
+1.5%Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.
Advisor
Compensation
$642,747
Chief Legal and Administration Officer & Corporate Secretary
Director of Internal Audit & Chief Compliance Officer
EVice President & Chief Financial Officer
Executive Vice President of Quality & Development Services
President of Curation Foods, Inc.
Compensation
$1,341,438
President, Chief Executive Officer & Director
Compensation
$135,557
Senior Vice President of Operations
Vice President
Compensation
$321,908
During the last 12 months, insiders have sold $985K worth of LFCR shares, with no buying activity reported.
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
0
0.00
121.6K
985.03K
-985K
-$985K
No buying activity
Josephs Paul
Director, Officer: Chief Executive Officer
$449K
Lake Ryan David
Officer: Chief Financial Officer
$445K
Salus Thomas D.
Officer: Chief Legal & Administration
$90K
Strong bearish signal with $985K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
3 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
LFCR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | April 24, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | September 18, 2025 | September 18, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | February 27, 2025 | February 27, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | September 23, 2024 | November 07, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | July 19, 2024 | May 28, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | September 19, 2022 | September 19, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | August 27, 2021 | October 20, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | August 31, 2020 | October 14, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | August 21, 2019 | October 16, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | August 23, 2018 | October 12, 2018 | 2018 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.